• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The prime time for management of hepatocellular carcinoma in Hong Kong.

作者信息

Chan Landon L, Chan Stephen L

机构信息

Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.

DOI:10.3350/cmh.2023.0094
PMID:36907571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121297/
Abstract
摘要

相似文献

1
The prime time for management of hepatocellular carcinoma in Hong Kong.香港肝细胞癌的最佳治疗时机。
Clin Mol Hepatol. 2023 Apr;29(2):345-348. doi: 10.3350/cmh.2023.0094. Epub 2023 Mar 9.
2
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?经动脉化疗栓塞术与索拉非尼治疗中期肝细胞癌患者：是时候进入常规临床实践了吗？
Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.
3
Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.乐伐替尼联合经动脉化疗栓塞术对不可切除肝细胞癌（uHCC）是否有益？年龄干扰因素需要排除。
Hepatol Int. 2024 Apr;18(2):704-705. doi: 10.1007/s12072-023-10611-z. Epub 2023 Nov 9.
4
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞术治疗肝细胞癌。
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
5
Treatment of intermediate-stage hepatocellular carcinoma.中期肝细胞癌的治疗
Clin Adv Hematol Oncol. 2015 Aug;13(8):501-3.
6
Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.在采用仑伐替尼、经动脉化疗栓塞术和卡瑞利珠单抗进行降期治疗后，对晚期肝细胞癌进行肝移植
Br J Surg. 2024 Mar 2;111(3). doi: 10.1093/bjs/znae048.
7
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.肝细胞癌的临床实践指南和实际实践：香港的观点。
Clin Mol Hepatol. 2023 Apr;29(2):217-229. doi: 10.3350/cmh.2022.0399. Epub 2022 Dec 28.
8
[Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].[肝细胞癌的切除术或介入治疗：哪种方法适用于哪种患者？]
Dtsch Med Wochenschr. 2013 Sep;138(36):1780-4. doi: 10.1055/s-0033-1343347. Epub 2013 Aug 13.
9
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.早期仑伐替尼给药对中期肝细胞癌患者生存的影响：一项多中心、逆概率加权分析。
Oncology. 2021;99(8):518-527. doi: 10.1159/000515896. Epub 2021 Apr 27.
10
Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization.经动脉化疗栓塞术后中国患者香港肝癌分期系统的多中心评估
Cardiovasc Intervent Radiol. 2018 Dec;41(12):1867-1876. doi: 10.1007/s00270-018-2023-z. Epub 2018 Aug 2.

本文引用的文献

1
Systemic therapy in advanced hepatocellular carcinoma.晚期肝细胞癌的全身治疗
Clin Mol Hepatol. 2023 Apr;29(2):516-519. doi: 10.3350/cmh.2023.0051. Epub 2023 Feb 20.
2
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.肝细胞癌的临床实践指南和实际实践：香港的观点。
Clin Mol Hepatol. 2023 Apr;29(2):217-229. doi: 10.3350/cmh.2022.0399. Epub 2022 Dec 28.
3
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease.全国性肝细胞癌监测对慢性肝病患者预后的影响。
Clin Mol Hepatol. 2022 Oct;28(4):851-863. doi: 10.3350/cmh.2022.0037. Epub 2022 Jun 3.
4
Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?基于血液的肝细胞癌筛查生物标志物：即将结束超声时代？
J Hepatol. 2023 Jan;78(1):207-216. doi: 10.1016/j.jhep.2022.08.036. Epub 2022 Sep 8.
5
Breast Cancer in Asia: Incidence, Mortality, Early Detection, Mammography Programs, and Risk-Based Screening Initiatives.亚洲的乳腺癌：发病率、死亡率、早期检测、乳房X光检查项目以及基于风险的筛查举措
Cancers (Basel). 2022 Aug 30;14(17):4218. doi: 10.3390/cancers14174218.
6
Surveillance for hepatocellular carcinoma: It is time to move forward.肝细胞癌监测：是时候向前迈进了。
Clin Mol Hepatol. 2022 Oct;28(4):810-813. doi: 10.3350/cmh.2022.0257. Epub 2022 Sep 6.
7
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).仑伐替尼联合经动脉化疗栓塞术作为晚期肝细胞癌一线治疗的III期随机临床试验（LAUNCH）
J Clin Oncol. 2023 Jan 1;41(1):117-127. doi: 10.1200/JCO.22.00392. Epub 2022 Aug 3.
8
Personalized treatment for hepatocellular carcinoma: Current status and future perspectives.肝细胞癌的个体化治疗：现状与展望。
J Gastroenterol Hepatol. 2022 Jul;37(7):1197-1206. doi: 10.1111/jgh.15889. Epub 2022 May 25.
9
Current and future colorectal cancer screening strategies.当前和未来的结直肠癌筛查策略。
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):521-531. doi: 10.1038/s41575-022-00612-y. Epub 2022 May 3.
10
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.